Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

TD Cowen downgraded Hims & Hers Health to "Hold" from "Buy" citing a lack of near-term catalysts and concerns over the company’s weight loss revenue guidance in a post-compounded GLP-1 ...

SHOPPING: Take steps to achieve your body goals with Hers, the weight loss program that takes into account your specific ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week ...

Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...

The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.